1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
2Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
3Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
4Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
↵†To whom correspondence should be addressed. E-mail: livio.trusolino{at}ircc.it (L.T.) and paolo.comoglio{at}ircc.it (P.M.C.)
↵* These authors contributed equally to this work.
See allHide authors and affiliations
Science Signaling 08 Dec 2009: Vol. 2, Issue 100, pp. ra80 DOI: 10.1126/scisignal.2000643
Andrea Bertotti
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
3Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
By Andrea Bertotti, Mike F. Burbridge, Stefania Gastaldi, Francesco Galimi, Davide Torti, Enzo Medico, Silvia Giordano, Simona Corso, Gaëlle Rolland-Valognes, Brian P. Lockhart, John A. Hickman, Paolo M. Comoglio, Livio Trusolino
Science Signaling : ra80
Cells addicted to different oncogenic receptor tyrosine kinases develop common downstream mechanisms to sustain malignancy.
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
By Andrea Bertotti, Mike F. Burbridge, Stefania Gastaldi, Francesco Galimi, Davide Torti, Enzo Medico, Silvia Giordano, Simona Corso, Gaëlle Rolland-Valognes, Brian P. Lockhart, John A. Hickman, Paolo M. Comoglio, Livio Trusolino
Science Signaling : ra80
Cells addicted to different oncogenic receptor tyrosine kinases develop common downstream mechanisms to sustain malignancy.